Table 3.
Markers of bacterial translocation, inflammation, pro-coagulation and very low-level viremia
| PI Monotherapy (n=40) | IP-containing triple therapy (n=20) | p | |
|---|---|---|---|
| Bacterial translocation | |||
| LBP (ng/ml) | 8948 (8115–10,999) | 8237 (7171–9693) | 0.07 |
| sCD14 (ng/ml) | 2133.18 (1847.13–2387.14) | 1714.36 (1460.53–1904.20) | 0.004 |
| EndoCAb (MMU/ml) | 68 (44–99) | 74 (34–105) | 0.47 |
| sCD163 (ng/ml) | 368 (279.76–530.90) | 215.38 (147.18–292.23) | 0.002 |
| Inflammation | |||
| hs-CRP (mg/dl) | 0.2 (0.08–0.46) | 0.18 (0.09–0.33) | 0.72 |
| IL-6 (pg/ml) | 34.5 (18–258) | 8 (8–27.5) | 0.04 |
| TNFα (pg/ml) | 5 (4–7) | 4.5 (4–7) | 0.27 |
| Pro-coagulation | |||
| D-dimer (ng/ml) | 201 (90–320) | 176 (111–269) | 0.23 |
| Viremia | |||
| Detection of VLLV. n (%) | 15/38 (39.4) | 2/18 (11) | 0.03 |
LBP=Lipopolysaccharide-binding protein; sCD14=soluble CD14; EndoCAb=endotoxin core IgM antibody; sCD163=soluble CD163; hs-CRP=high sensitive C-reactive protein; IL-6=interleukin-6; VLLV=very low-level viremia. Data are in median (IQR) unless otherwise indicated.